Literature DB >> 14670767

Central core disease: clinical, pathological, and genetic features.

R M Quinlivan1, C R Muller, M Davis, N G Laing, G A Evans, J Dwyer, J Dove, A P Roberts, C A Sewry.   

Abstract

Central core disease (CCD) is a dominantly inherited congenital myopathy allelic to malignant hyperthermia (MH) caused by mutations in the RYR1 gene on chromosome 19q13.1. Eleven individuals with RYR1 mutations are described. Four index cases showed features consistent with a congenital myopathy (hypotonia, delayed motor milestones, and skeletal abnormalities including congenital hip dislocation and scoliosis). All four cases and subsequently seven other family members were found to possess novel mutations in the RYR1 gene. The degree of disability varied from one clinically normal individual, to another who had never achieved independent ambulation (the only patient with a de novo mutation). Four cases showed a mild reduction in vital capacity, repeated nocturnal polysomnography showed hypoxaemia in one case. A variety of muscle biopsy features were found; central cores were absent in the youngest case, and the biopsy specimens from two others were more suggestive of mini-core myopathy. In all cases missense mutations in exons 101, 102, and 103 of the RYR1 gene on were found. Future laboratory diagnosis of suspected cases and family members will be less invasive and more accurate with DNA analysis. Clinicians, especially paediatricians and orthopaedic surgeons, should be aware of this disorder because of the potential risk of MH.

Entities:  

Mesh:

Year:  2003        PMID: 14670767      PMCID: PMC1719384          DOI: 10.1136/adc.88.12.1051

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  15 in total

1.  The spectrum of pathology in central core disease.

Authors:  C A Sewry; C Müller; M Davis; J S M Dwyer; J Dove; G Evans; R Schröder; D Fürst; T Helliwell; N Laing; R C M Quinlivan
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

2.  Central core disease and congenital neuromuscular disease with uniform type 1 fibers in one family.

Authors:  M Tojo; M Ozawa; I Nonaka
Journal:  Brain Dev       Date:  2000-06       Impact factor: 1.961

3.  A new congenital non-progressive myopathy.

Authors:  K R MAGEE; G M SHY
Journal:  Brain       Date:  1956-12       Impact factor: 13.501

4.  Central core disease: ultrastructure of the sarcoplasmic reticulum and T-tubules.

Authors:  K Hayashi; R G Miller; A K Brownell
Journal:  Muscle Nerve       Date:  1989-02       Impact factor: 3.217

Review 5.  Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.

Authors:  M G Larach
Journal:  Anesth Analg       Date:  1989-10       Impact factor: 5.108

6.  Malignant hyperpyrexia in Australia and New Zealand.

Authors:  J O King; M A Denborough
Journal:  Med J Aust       Date:  1973-03-17       Impact factor: 7.738

Review 7.  Ryanodine receptor mutations in malignant hyperthermia and central core disease.

Authors:  T V McCarthy; K A Quane; P J Lynch
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

8.  Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor.

Authors:  N Monnier; N B Romero; J Lerale; P Landrieu; Y Nivoche; M Fardeau; J Lunardi
Journal:  Hum Mol Genet       Date:  2001-10-15       Impact factor: 6.150

9.  A severe clinical and pathological variant of central core disease with possible autosomal recessive inheritance.

Authors:  A Y Manzur; C A Sewry; J Ziprin; V Dubowitz; F Muntoni
Journal:  Neuromuscul Disord       Date:  1998-10       Impact factor: 4.296

10.  B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators.

Authors:  T Girard; D Cavagna; E Padovan; G Spagnoli; A Urwyler; F Zorzato; S Treves
Journal:  J Biol Chem       Date:  2001-10-22       Impact factor: 5.157

View more
  20 in total

1.  Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants.

Authors:  Senthilkumar Sadhasivam; Barbara W Brandom; Richard A Henker; John J McAuliffe
Journal:  Pharmacogenomics       Date:  2019-09       Impact factor: 2.533

2.  Consensus statement on standard of care for congenital myopathies.

Authors:  Ching H Wang; James J Dowling; Kathryn North; Mary K Schroth; Thomas Sejersen; Frederic Shapiro; Jonathan Bellini; Hali Weiss; Marc Guillet; Kimberly Amburgey; Susan Apkon; Enrico Bertini; Carsten Bonnemann; Nigel Clarke; Anne M Connolly; Brigitte Estournet-Mathiaud; Dominic Fitzgerald; Julaine M Florence; Richard Gee; Juliana Gurgel-Giannetti; Allan M Glanzman; Brittany Hofmeister; Heinz Jungbluth; Anastassios C Koumbourlis; Nigel G Laing; Marion Main; Leslie A Morrison; Craig Munns; Kristy Rose; Pamela M Schuler; Caroline Sewry; Kari Storhaug; Mariz Vainzof; Nanci Yuan
Journal:  J Child Neurol       Date:  2012-03       Impact factor: 1.987

3.  Mild Clinical Features and Histopathologically Atypical Cores in Two Korean Families with Central Core Disease Harboring RYR1 Mutations at the C-Terminal Region.

Authors:  Na-Yeon Jung; Yeong-Eun Park; Jin-Hong Shin; Chang Hun Lee; Dae-Soo Jung; Dae-Seong Kim
Journal:  J Clin Neurol       Date:  2014-11-11       Impact factor: 3.077

4.  Isolation of bastadin-6-O-sulfate and expedient purifications of bastadins-4, -5 and -6 from extracts of Ianthella basta.

Authors:  Christopher J Gartshore; Mariam N Salib; August A Renshaw; Tadeusz F Molinski
Journal:  Fitoterapia       Date:  2017-12-05       Impact factor: 2.882

5.  Progressive scoliosis in central core disease.

Authors:  Kirsten D Mertz; Bernhard Jost; Markus Glatzel; Kan Min
Journal:  Eur Spine J       Date:  2005-05-31       Impact factor: 3.134

6.  Kyphoscoliosis associated with congenital neuromuscular disease with uniform type 1 fibers.

Authors:  Shiro Imagama; Noriaki Kawakami; Taichi Tsuji; Tetsuya Ohara; Naoki Ishiguro
Journal:  Eur Spine J       Date:  2011-12-23       Impact factor: 3.134

7.  Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.

Authors:  Barbara W Brandom; Saiid Bina; Cynthia A Wong; Tarina Wallace; Mihaela Visoiu; Paul J Isackson; Georgirene D Vladutiu; Nyamkhishig Sambuughin; Sheila M Muldoon
Journal:  Anesth Analg       Date:  2013-04-04       Impact factor: 5.108

8.  A double mutation of the ryanodine receptor type 1 gene in a malignant hyperthermia family with multiminicore myopathy.

Authors:  Seul-Ki Jeong; Dong-Chan Kim; Yong-Gon Cho; Il-Nam Sunwoo; Dal-Sik Kim
Journal:  J Clin Neurol       Date:  2008-09-30       Impact factor: 3.077

Review 9.  The disorders of the calcium release unit of skeletal muscles: what have we learned from mouse models?

Authors:  Marta Canato; Paola Capitanio; Carlo Reggiani; Lina Cancellara
Journal:  J Muscle Res Cell Motil       Date:  2014-11-26       Impact factor: 2.698

10.  Malignant hyperthermia.

Authors:  Dong-Chan Kim
Journal:  Korean J Anesthesiol       Date:  2012-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.